PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) — Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staringâ€

... read more at: http://markets.businessinsider.com/news/stocks/INSYS-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Cannabidiol-CBD-Oral-Solution-for-Treatment-of-Refractory-Childhood-Absence-Epilepsy-in-Pediatric-PatientsProof-of-concept-study-aims-to-1011641158